Eli Lilly Launches Groundbreaking Weight-Loss Drug Mounjaro in India

The once-weekly injectable, priced significantly lower than in Western markets, addresses India's growing obesity and diabetes crises.

Mounjaro, a first-of-its-kind drug targeting obesity and type 2 diabetes, is now available in India following CDSCO approval.
The drug activates dual hormone receptors, GIP and GLP-1, to regulate appetite, reduce weight, and improve glycemic control.
Clinical trials showed significant weight loss, with participants losing up to 21.8 kg over 72 weeks when combined with diet and exercise.
Priced at ₹3,500 for a 2.5 mg dose and ₹4,375 for a 5 mg dose, it is much more affordable in India compared to U.S. pricing.
Experts emphasize the need for medical supervision to ensure safe use, particularly for non-diabetic patients seeking weight management.